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Background: Vinflunine (VFL) is a microtubule-targeting drug that suppresses microtubule dynamics, showing
anti-metastatic properties both in vitro and in living cancer cells. An increasing body of evidence underlines the
influence of the microtubules dynamics on the cadherin-dependent cell-cell adhesions. E-cadherin is a marker
of epithelial-to-mesenchymal transition (EMT) and a tumour suppressor; its reduced levels in carcinoma are associated
with poor prognosis. In this report, we investigate the role of VFL on cell-cell adhesions in bladder epithelial tumour
cells.
Methods: Human bladder epithelial tumour cell lines HT1376, 5637, SW780, T24 and UMUC3 were used to analyse
cadherin-dependent cell-cell adhesions under VFL treatment. VFL effect on growth inhibition was measured by using a
MTT colorimetric cell viability assay. Western blot, immunofluorescence and transmission electron microscopy analyses were
performed to assess the roles of VFL effect on cell-cell adhesions, epithelial-to-mesenchymal markers and apoptosis.
The role of the proteasome in controlling cell-cell adhesion was studied using the proteasome inhibitor MG132.
Results: We show that VFL induces cell death in bladder cancer cells and activates epithelial differentiation of the
remaining living cells, leading to an increase of E-cadherin-dependent cell-cell adhesion and a reduction of mesenchymal
markers, such as N-cadherin or vimentin. Moreover, while E-cadherin is increased, the levels of Hakai, an E3 ubiquitin-ligase
for E-cadherin, were significantly reduced in presence of VFL. In 5637, this reduction on Hakai expression was blocked by
MG132 proteasome inhibitor, indicating that the proteasome pathway could be one of the molecular mechanisms involved
in its degradation.
Conclusions: Our findings underscore a critical function for VFL in cell-cell adhesions of epithelial bladder tumour
cells, suggesting a novel molecular mechanism by which VFL may impact upon EMT and metastasis.
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Bladder cancer is a common malignancy affecting the
genitourinary system that represents the fifth most com-
mon cancer in the world. Transitional cell carcinoma
(TCC) represents 95% of these tumours [1]. Most blad-
der cancers (70%-80%) present non-muscle invasive or
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unless otherwise stated.or lamina propria (T1), and the remaining (20%-30%)
are muscle-invasive at the time of diagnosis (T2-T4) [2].
Although both bladder cancers originate from urothe-
lium in the urinary bladder (the epithelium that lines the
urinary tract), they have different clinical characteristics.
Muscle invasive TCC of the bladder is associated with a
high frequency of metastasis, resulting in poor prognosis
for patients [3]. Therefore, an effective strategy for pre-
venting the progression of bladder cancer is clearly
needed.
Epithelial cells bind to each other, forming a strong
adhesive cell layer with important barrier functions.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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but adherens junctions are the major cell–cell junc-
tions that mediate cell recognition, adhesion, morpho-
genesis, and tissue integrity. Adherens junctions are
linked to the actin cytoskeleton, establishing molecular
communication with other cell–cell junctions and
cell–substratum adhesions, and are involved in the
organization and movement of the cells within the epi-
thelium and in the transmission of information to the
interior of the cell. The most important mediators of
cell-to-cell adhesion are the transmembrane proteins
called cadherins. E- and N-cadherin were the first cad-
herins identified [4]. E-cadherin is the prototype and best-
characterized member of adherens junctions in mammalian
epithelial cells. It contains an extracellular domain that
forms homophilic interactions in a calcium-dependent man-
ner and is responsible for cell-to-cell adhesions, and a cyto-
plasmic domain linked to the actin cytoskeleton through its
interaction with several catenins [5,6]. E-cadherin is
regarded as a tumour suppressor and its loss is associ-
ated with poor prognosis in carcinoma.
E-cadherin is considered a hallmark of epithelial-to-
mesenchymal transition (EMT). EMT is an early step
during carcinoma metastasis characterized by the loss of
epithelial morphology and the acquisition of mesenchy-
mal and motile characteristics, resulting from the loss of
apical-basal polarity, the loss of cell–cell contacts, and
the reorganization of the actin cytoskeleton [7-9]. Nu-
merous studies suggest that EMT is associated with can-
cer cell invasion, recurrence, progression and metastasis
in various malignancies, including bladder cancer [10].
However, the EMT is a reversible transitional process, as
the cells can return to their epithelial phenotype: a
process that is known as mesenchymal-to-epithelial
transition [11]. The loss of E-cadherin expression may
also have a pivotal role in tumour progression character-
ized by increased mobility and invasiveness in bladder
cancer [12-14]. Indeed, several studies on the prognostic
role of E-cadherin in bladder cancer have shown that its
aberrant expression is associated to tumour progression
and poor prognosis [15]. A key change that occurs dur-
ing EMT is the "cadherin switch", in which the normal
expression of E-cadherin is replaced by the abnormal ex-
pression of N- or P-cadherin [16,17]. Another important
marker frequently used in cells undergoing EMT during
metastatic progression is vimentin. Vimentin is an inter-
mediate filament protein that is also upregulated during
EMT. Vimentin expression induces cell changes includ-
ing mesenchymal cell shape, increased cell motility, and
loss of adhesion in epithelial cells during EMT [18].
Other studies have also suggested that transcriptional
and posttranscriptional regulators are involved in the
control of EMT [19,20]. E-cadherin is also regulated at
posttranslational level; Hakai was the first posttranslationalregulator of E-cadherin stability [19,21]. Hakai is a RING
finger-type E3 ubiquitin-ligase for the E-cadherin complex
that mediates E-cadherin ubiquitination, endocytosis and
degradation; in consequence, it disrupts cell-cell contacts.
Moreover, many articles have described the emerging bio-
logical functions for Hakai protein pointing out its influ-
ence on tumour progression during EMT, proliferation,
and oncogenesis [21-28].
The microtubule system, a major component of the
cytoskeleton, was identified as a suitable target for can-
cer therapy, primarily based on their biological import-
ance in coordinating chromosome segregation during
mitosis. Microtubules are macromolecular filaments
composed of tubulin. The clinical efficacy of the first-
generation vinka alkaloid has prompted further research
for novel analogues with improved clinical efficacy and
safety. Such efforts have led to the development of vinflu-
nine (VFL), a third-generation, semi-synthetic vinca alkal-
oid that, similar to other microtubule-targeting drugs,
suppresses microtubule dynamics both in vitro and in
living cancer cells [29,30]. In contrast to other vinca
alkaloids, VFL shows superior antitumor activity and
an excellent safety profile. VFL was approved by the
European Medicines Agency (EMEA) as a second-line
treatment for patients with urothelial carcinoma resist-
ant to first-line platinum-containing chemotherapy
[31,32]. VFL has shown anti-angiogenic, anti-vascular
and anti-metastatic properties in vitro and in vivo [33].
Some potential underlying mechanisms of the anti-
angiogenic property of microtubule targeting-agents have
been reviewed [34,35]. Interestingly, in endothelial cells, it
was shown that microtubule-targeting agents, including
VFL, may produce their anti-migratory/anti-angiogenic
effects through an increase in interphase microtubule
dynamics. In endothelial cells, at low and non-cytotoxic
concentrations, VFL inhibits cell motility [36].
Although cadherins are best understood to cooperate
with the actin cytoskeleton, there is increasing evidence
supporting a role of the microtubules in regulating cad-
herin biology. Indeed, the cross-talk between micro-
tubule networks and cell-cell adhesion sites profoundly
impact upon these structures and is essential for
proper cell organization, polarization and motility
[37-42]. In the current study, we wanted investigate
the possible impact of the microtubule-targeting drug
VFL on E-cadherin-based cell-cell adhesion, and to de-
termine the possible influence on the EMT transition
markers in epithelial bladder tumour cell lines. We de-
scribe that VFL induces cell death in bladder cancer
cells and activates epithelial differentiation of the
remaining living cells. It has an impact on cell-cell contact,
leading to an increase E-cadherin dependent cell-cell adhe-
sion, while reducing vimentin and N-cadherin mesenchymal
markers. Moreover, the levels of the E3 ubiquitin-ligase
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lines tested. Moreover, this reduction in Hakai protein levels
was recovered in presence of the proteasome inhibitor
MG132 in 5637 cell line, suggesting that Hakai could be, at
least, partially degraded in a proteasome-dependent manner.
Our data suggest that VFL may be involved in a cross-talk
between microtubule networks and cell-cell adhesion sites
by its function as a microtubule-targeting drug, suggesting a
novel molecular mechanism by which VFL may impact
upon EMTand metastasis.Methods
Cell culture and treatments
Human bladder epithelial tumour cell lines HT1376,
5637, UMUC3, SW780 and T24 were used. HT1376 cell
line was obtained from American Type Culture Collec-
tions (Manassas, VA). UMUC3 and SW780 were gener-
ously donated by Dr. F. Garcia (Pharmamar S.A., Madrid)
and 5637 and T24 by Dr. F. Real (Spanish National Cancer
Research Centre from Madrid, Spain). HT1376 and
UMUC3 cells were cultured in DMEM medium (Gibco,
LifeTech), 5637 was cultured in RPMI medium (Gibco,
LifeTech), SW780 was cultured in Leibovitz’s medium
(Gibco, LifeTech) and T24 cell line was culture in
McCoy’s 5A (Gibco, LifeTech); each media was sup-
plemented with 100 U/ml penicillin, 100 μg/ml strepto-
mycin, 1% L-glutamine and 10% foetal bovine serum.
Cultures were maintained at 37ºC with 5% CO2 in a hu-
midified incubator. HT1377 cells were grown in the
indicated medium additionally supplemented with non-
essential aminoacids (Gibco, LifeTech). A stock solution
of vinflunine was prepared in distilled water. Cells were
treated with VFL at the indicated final concentrations and
for the times shown. MG132 was obtained from Sigma-
Aldrich (St Louis, USA) and was added to the medium at
final concentration of 20 μM for 2 hours.Antibodies and reagents
Antibodies were used that recognized the cytoplasmic por-
tion of E-cadherin (Invitrogen, California, USA), Hakai
(Hakai-2498, kindly provided by Dr. Yasuyuki Fujita [14]),
N-cadherin (Abcam, Cambridge, UK), vimentin (Cell Sig-
naling Technology, Massachussetts, USA), cyclin D1 (Santa
Cruz Biotechnology, Texas, USA), and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) (Invitrogen, California,
USA). HRP-rabbit and mouse polyclonal antibodies were
from GE Healthcare (Uppsala, Sweden) and Alexa Fluor
488 secondary antibody was from Invitrogen (UK). All anti-
bodies were used at dilutions of 1:1000 for Western blot
analysis, except for HRP-rabbit, mouse polyclonal anti-
bodies, and anti-GAPDH antibodies that were used at
1:2000, 1:2000, and 1:10000 respectively. E-cadherin anti-
body (BD Bioscence, California, USA) was used forimmunofluorescence at a dilution of 1:500 and Alexa Fluor
488 secondary antibody was used at a dilution of 1:100.
Viability assay
For cytotoxicity assays, 1 × 104 cells were plated per well
into a 96-well plate and cultured for 24 h before treat-
ment with VFL for 48 h. Serial dilutions of VFL dis-
solved in fresh medium were added to the cells in fresh
medium. Growth inhibition of the epithelial tumour
bladder cell lines was measured by using a MTT colori-
metric cell viability assay kit (Sigma Aldrich, St Louis,
MO) according to the manufacturer’s instructions. To
measure absorbance at 570 nm, a Multiskan Plus Reader
(Thermo Fisher, MA, USA) was used. The half-maximal
inhibitory concentration (IC50) and the corresponding
95% confidence interval (95% CI) values were calculated
from dose–response curves constructed using GraphPad
Prism software. The data presented are the average of
three independent experiments performed six times.
Phase contrast microscopy
For phase-contrast images, 2 × 105 cells were plated per
well in a 6-well plate and treated with the indicated final
concentrations of VFL (VFL) during 48 h. Cells were
then fixed with 4% paraformaldehyde in phosphate-
buffered saline (PBS) for 15 min. Phase-contrast images
were acquired using a Nikon Eclipse-Ti microscope.
Protein analysis
Protein was isolated using TriPure Reagent (Roche,
Germany) according to the manufacturer’s instructions.
Cell lysates (20 μg of proteins) were obtained by lysing
cells in a buffer containing 1% Triton X-100 (20 mM
Tris/HCl pH 7.5, 150 mM NaCl and 1% Triton X-100),
a protease inhibitor cocktail (Sigma Aldrich, St Louise,
USA), and 50 mM PMSF. Western blot analysis was per-
formed as described previously [43].
Transmission electron microscopy
For transmission electron microscopy, 5 × 104 cells of
5637 bladder tumour cell line were plated into 0.4 μm-
pore culture inserts (Corning 353095, USA) placed on a
24-well plate. After treatment with 5 μM of VFL during
48 hours, cells were fixed with 2.5% cold glutaraldehyde
(Panreac, Spain) in 0.1 M sodium cacodylate buffer
(Sigma-Aldrich, Germany) pH 7.4, for 16 h at 4°C. In-
serts were postfixed in 1% osmium tetroxide in 0.1 M
sodium cacodylate buffer, pH 7.4, for 1 h at room
temperature, following by several washes with 0.1 M so-
dium cacodylate buffer and distilled water. Inserts were
dehydrated in increasing concentrations of acetone and
embedded in Spurr’s resin (Taab, Berkshire, UK). Ultra-
thin sections of 70– to 80-nm thickness were cut using
an Ultracut-E ultramicrotome (Leica) and collected on
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ined with a JEOL JEM 1010 transmission electron
microscope at 80 kV.
Immunofluorescence and TUNEL assay
For immunofluorescence and TUNEL assay, 3 × 104 cells
were plated in chambers slides (Millipores, USA), fixed in
4% paraformaldehyde for 10 min, and then permeabilized
in 0.5% Triton X-100-phosphate buffered saline (PBS) for
15 min. Cell death was measured by using Click-it
TUNEL Alexa Fluor® 594 Imaging Assay (Invitrogen, UK)
according to manufacturer’s instructions followed by
blocking with BSA 3% in PBS for 1 h. Incubation with
E-cadherin primary antibody for 1 h was followed by
incubation in Alexa-Fluor 488-conjugated secondary
antibody solution for 1 h. To visualize nuclei, it was
used 4',6-Diamidino-2-Phenylindole, Dihydrochloride
(DAPI, LifeTech, UK).Finally, the mounting media used
was ProLong Gold antifade reagent (LifeTech, USA). Epi-
fluorescence images were taken in Olympus microscope.
RNA analysis
Total RNA was isolated using TriPure Reagent (Roche,
Germany) according to manufacturer´s instruction. The
immunoprecipitated RNA pellet was washed by follow-
ing an alternative protocol described for small RNAs in
RiboPure (Life Technologies, UK). The quality and
quantity of the obtained RNA was determined by using
Nanodrop ND-spectrophotometer (Thermo Fisher
Scientific, MA, USA). For reverse transcription (RT),
random hexamers and SuperScript first-strand Syn-
thesis System for RT-PCR (Invitrogen, UK) were
used. For mRNA analysis, real-time quantitative (q)
PCR analysis was performed using gene-specific
primers 5’-CGCAGACGAATTCCTATAAAGC-3’ and
5’- CCTTCTTCATCACCAGGTGG -3’ for human
Hakai and 5’-TGACCTTGATTTATTTTGCATACC-3’
and 5’-CGAGCAAGACGTTCAGTCCT-3’ for HPRT.
PCR was performed by using Light Cycler 480 SYBR
Green I Master (Roche, Germany); amplification and
quantification were carried out using a LightCycler
480 real-time lightcycler (Roche, Germany).
Statistical analysis
Unless indicated, all experiments were analysed by using
Students t-test to evaluate differences between treat-
ments at the indicated significance levels.
Results
Vinflunine induces epithelial phenotype in bladder
tumour cells
VFL, a microtubule-targeting drug, is used in monother-
apy for treatment of advanced or metastatic urothelial
cancers in adults. Given the rising evidence of crosstalkbetween microtubule networks and cell-cell adhesion
sites, we sought to investigate the possible impact of
VFL on cell-cell adhesions in bladder epithelial tumour
cells. To this end, we first examined the effect of VFL on
cell viability of HT1376, 5637, SW780, T24 and UMUC3
bladder epithelial tumour cells by using increasing con-
centrations of VFL (0–100 μM) treatment for 48 h.
Figure 1 shows the dose-dependent inhibition of cell
growth observed: IC50 = 4.677 μM for HT1376, IC50 =
3.478 μM for 5637 cells, IC50 = 1.734 μM for SW780,
IC50 = 0.277 μM for UMUC3 cells and IC50 = 0.068 μM
for T24, the latest cell lines showing the highest sensi-
tivity to VFL. The cellular morphology following VFL
treatment was analysed by phase-contrast microscopy in
the indicated cell lines (Additional file 1 and Figure 2). As
shown, HT1376 and 5637 showed drastic changes, with a
morphology resembling that of epithelial cells, at VFL
doses ranging between 1–20 μM, and tighter cell–cell
contacts, as compared to control cells, which displayed a
fibroblast-like morphology with decreased cell–cell con-
tacts and increased numbers of membrane protrusions
(Figure 2). This effect was also observed in SW780 tumor
bladder cell line (data not shown). However, the fibroblas-
tic morphology of UMUC3 and T24 cell lines was not af-
fected by VFL treatment, showing an increased cell death,
even in the presence of lower VFL concentrations (Figure 2
and data not shown). In conclusion, VFL affects the fibro-
blastic phenotype in HT1376, 5637 and SW780 bladder
epithelial tumour cells, but not in UMUC3 and T24 cells.
VFL effect on epithelial-to-mesenchymal transition
markers
Given the different impact of VFL upon the presence of
cell-cell contacts among the analysed bladder tumour
cell lines, we set out to examine the endogenous levels
of several EMT markers in the different bladder epithe-
lial tumour cell lines. As shown in Figure 3A, important
differences were found between the analysed cell lines.
First, E-cadherin, a major epithelial marker that mediates
cell-to-cell adhesions, was only detected in HT1376,
5637 and SW780 cells (Figure 3A), precisely the cell
lines that were switched to a more epithelial-like phenotype
and are more resistant to VFL treatment. Non E-cadherin
expression was found in the cell lines that experienced the
most cytotoxicity in response to VFL (Figure 3A), such as
UMUC3 and T24. Interestingly, phenotypical changes
under VFL treatments were not detected in UMUC3
and T24 cell lines (Figure 1). It was also analysed the
expression level of N-cadherin and vimentin mesen-
chymal markers, which are frequently expressed in car-
cinoma cells that have undergone EMT. Together, these
data suggest that E-cadherin expressing bladder tumour
cells are more resistant to VFL and respond better to the
VFL-triggered switch from mesenchymal-to-epithelial
Figure 1 Effect of VFL on cytotoxicity of bladder tumour cell lines. The five indicated human tumour bladder cell lines (HT1376, 5637,
SW780 in upper panel; UMUC3 and T24 in bottom panel) were treated with increasing concentrations of VFL (0–100 μM) for 48 h. Cell viability
was determined by the MTT assay. A, HT1376. B, 5637. C, SW780. D, UMUC3 E, T24. Data are the means ± SEM of three independent experiments
represented by logarithmic scale, and the IC50 value and CI95% for each cell line are indicated.
VFL (μM)
5637
0 1 2 10
UMUC3
0 1 2 10
0 10 20
HT1376
2
Figure 2 Effect of VFL on the phenotype of bladder tumour cell lines. Phase-contrast microscopy images of the indicated bladder cell lines
taken 48 h after treatment with increasing concentrations of VFL compared to control conditions. Scale bar, 100 μm.
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Figure 3 Epithelial-to-mesenchymal markers. A, the endogenous
expression levels of the epithelial marker E-cadherin and mesenchymal
markers N-cadherin and vimentin were assessed in bladder tumour
cells (HT1376, SW780, UMUC3, T24 and 5637) by western blot analysis.
B, the effect of 5 μM VFL treatments of 5637 bladder tumour cells for
48 and 72 h on the indicated protein markers was assessed by western
blot analysis. C, Cyclin D1 expression levels were assessed by Western
blot analysis after treatment of 5637 bladder tumour cells for 48 and
72 h with VFL. Western blot data are representative of three independent
experiments and GAPDH antibody was used as loading control
for normalization.
5μM VFL Ctrl.
Cyt.
Cyt.
Cyt.
Cyt.
Nucl.
Nucl.
Figure 4 Analysis of cell-cell contacts by transmission electron
microscopy. 5637 bladder cell lines were either untreated (left panel)
or treated with 5 μM VFL 48 hours (right panel), whereupon cells were
analysed by transmission electron microscopy. Nucl.: nucleus; Cyt:
cytoplasm; Sites of close cell-cell contacts are shown (arrowheads),.
Scale bar, 2 μm.
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modulate cell death and epithelial cell differentiation.
VFL has an anti-metastatic property in vitro and
in vivo; in vitro invasion assays showed an inhibitory ef-
fect of VFL treatment on invasion ability in a transitional
cell carcinoma of the bladder. Moreover, in an orthoto-
pic murine model of transitional cell carcinoma of the
bladder, VFL showed potent high antitumor activity [44].
Since the initiation of metastasis requires invasion,
which is enabled by EMT, we were interested in deter-
mining whether VFL might regulate the levels of EMT
protein markers. A key change that occurs during EMT
is the “cadherin switch”, in which the normal expressionof E-cadherin is replaced by the abnormal expression of
N-cadherin [16,17]. Downregulation of E-cadherin, re-
sponsible for the loss of cell-cell adhesions, and upregula-
tion of mesenchymal-related proteins, such as vimentin or
N-cadherin, define the EMT process [9]. As shown in
Figure 3B, VFL treatment (5 μM) modestly increased
protein expression of E-cadherin after 48 and 72 hours
in 5637 bladder tumour cells; instead, the mesenchy-
mal N-cadherin marker was reduced under the treat-
ment. Moreover, the E3 ubiquitin-ligase Hakai for the
E-cadherin complex was significantly reduced under
these conditions, suggesting that the disappearance of
Hakai protein could influence the recovery of E-cadherin
expression. Hakai was also proposed to be involved in the
regulation of both cell–cell contacts and cell proliferation.
It was suggested that cyclin D1, a member of the cyclin
protein family involved in the regulation of the cell cycle
progression, was one of the substrate effector proteins
through which Hakai might regulate cell proliferation
[25]. Indeed, VFL treatment of 5637 cells caused a reduc-
tion in cyclin D1 protein levels compared to control con-
ditions, while Hakai was also decreased (Figure 3C). In
addition, transmission electron microscopy indicated that
neighbouring VFL-treated E-cadherin expressing 5637
cells had very closely apposed cell-cell contacts compared
to control cells (Figure 4). We extended this study in other
bladder tumour epithelial cells. As shown in Figure 5A, in
HT1376, VFL treatment modestly increases E-cadherin
protein levels while Hakai is reduced; these cells do not ex-
press the mesenchymal markers vimentin or N-cadherin. By
immunofluorescent staining, the VFL-elevated E-cadherin
was detected at cell-cell contacts in epithelial cells
(Figure 5B) while a reduction of E-cadherin protein at
cell-cell was observed in cells undergoing apoptosis
(Figure 5C). Finally, in UMUC3 cells, which do not ex-
press E-cadherin, it was shown that Hakai, vimentin,
+ VFL (5 μM)
48h
-
+ VFL (5 μM)
48h
GAPDH
E-cadherin
Hakai
HT1376
-
Hakai
E-cadherin
GAPDH
-
48h
M 5 M
UMUC3
N-cadherin
VFL (μM)
VFL (5 μM)
-
E-cadherin TUNEL DAPI Merge
HT1376
HT1376
BA
C
D
2 μ μ
Figure 5 Effect of VFL on epithelial differentiation and apoptosis. A, Western blot analysis of E-cadherin and Hakai expression levels in
HT1373 bladder tumour cells treated with 5 μM VFL for 48 h. B, immunofluorescence analysis of E-cadherin expression in HT1376 cells treated
with 5 μM VFL for 48 hours. Scale bar, 200 μM. C, TUNEL staining for the analysis of apoptosis was performed following by immunofluorescence
of E-cadherin in HT1376 cells treated with 5 μM VFL for 48 hours, as indicated in material and methods. Scale bar, 50 μM. D, Western blot analysis
of the levels of E-cadherin, Hakai, N-cadherin and vimentin in UMUC3 bladder tumour cells treated with 5 μM VFL for 48 hours. Western blots are
representative of three independent experiments and GAPDH was assessed as loading control.
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flunine treatment (Figure 5D). Taken together, these
data suggest that VFL causes cell death and epithelial
cell differentiation in the E-cadherin-expressing cells.
VFL promotes proteasome-mediated Hakai degradation
Since VFL causes a reduction in Hakai protein levels, we
examined whether VFL affects Hakai mRNA levels using
reverse transcription (RT) followed by real-time, quanti-
tative (q) PCR. In contrast with Hakai protein levels,Hakai mRNA levels were not downregulated by VFL
treatment in 5637, HT1376 and UMUC3 (Figure 6A),
suggesting that VFL lowers Hakai protein levels without
decreasing Hakai mRNA abundance. Previous studies
demonstrated that in all tissues, the majority of intracel-
lular proteins are degraded by the ubiquitin proteasome
pathway [45]. However, extracellular proteins and some
cell surface proteins are taken up by endocytosis and de-
graded within lysosomes. Given that Hakai is an intracel-
lular protein, we investigated whether the reduced Hakai
VFL (5 μM) +- VFL (5 μM) +-
+VFL (5 μM) -
Hakai
E-cadherin
GAPDH
VFL (5 μM)
MG132 (20 μM)
+- +
- +-
VFL (5 μM)
MG132 (20 μM)
+- +
- +-
ex
pr
es
si
on
ex
pr
es
si
on
5637
ex
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on
UMUC3
HT1376
ex
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on
20
40
60
80
100
E-cadherin
Hakai
120
*
*
**
**
**
*
5637
A
B
Figure 6 VFL is involved in Hakai degradation via proteasome-mediated in 5637 cell line. A, the levels of Hakai mRNA in 5637 (upper
panel, left), HT1376 (upper panel, right), and UMUC3 (lower panel) cells following treatment with 5 μM VFL for 48 hours were determined by
RT-qPCR analysis. HPRT mRNA levels were measured for normalization. The means ± SEM are represented from three independent experiments
(*p < 0.05, n = 3). B, effect of proteasome inhibitor, MG132, on Hakai expression in 5637. Cells following treatment with 5 μM VFL for 48 hours were
incubated for 2 h in the absence or presence of proteasome inhibitor (20 μM MG132) and cell lysates were prepared for Western blot analysis
to detect Hakai, E-cadherin and normalization control GAPDH. Western blot data are representative of three independent experiments and quantification
by densitometry was represented (lower panel, *p < 0.05, **p < 0.01).
Aparicio et al. BMC Cancer 2014, 14:507 Page 8 of 13
http://www.biomedcentral.com/1471-2407/14/507
Aparicio et al. BMC Cancer 2014, 14:507 Page 9 of 13
http://www.biomedcentral.com/1471-2407/14/507levels in VFL-treated cells could be affected by the in-
creased degradation via proteasome of Hakai protein.
We analyzed the effect of the proteasome inhibitors
MG132 in VFL-treated 5637 cells compared to control
conditions. As shown in Figure 6B, treatment of 5637
bladder cancer cells with VFL consistently reduced Hakai
protein levels; however, the addition of MG132 inhibited
this VFL-mediated-Hakai down-regulation. As expected,
given that Hakai protein levels are restored by MG132
treatment, E-cadherin is reduced under these conditions.
In conclusion, in 5637 cell lines Hakai reduction can be
recovered by using proteasome inhibitors, MG132, further
supporting the notion that Hakai down-regulation in-
duced by VFL can be at least partially controlled in a
proteasome-dependent mechanism.
Discussion
The transitional cell carcinomas of the bladder that in-
vade muscle are associated with high frequency of me-
tastasis, which is the major cause of death from cancer.
Microtubules, a major component of the cytoskeleton,
are one of the best established targets for cancer therapy.
Indeed, the microtubule-targeting drug VFL, which sup-
presses microtubule dynamics in vitro and in vivo, is the
recommended option treatment of metastatic transi-
tional cell carcinoma of the urothelial tract which has
progressed after treatment with platinum-containing
chemotherapy. Given the increasing body of evidence
supporting that microtubules regulate cadherin biology,
and the well-established role of E-cadherin in the EMT
during bladder cancer progression and metastasis, here
we have studied the effect of VFL on E-cadherin cell-cell
adhesions. Using bladder cancer cell lines, we have
shown that VFL treatment induces cell death in bladder
cancer cells and activates epithelial differentiation in the
remaining cells, leading to increased E-cadherin-dependent
cell-cell adhesions and to reduced levels of mesenchymal
markers, such as N-cadherin or vimentin. Moreover, we
have demonstrated that Hakai, a post-translational regula-
tor of E-cadherin stability, was significantly reduced in a
VFL-dependent manner in 5637 suggesting that the prote-
asome pathway is at least partially involved in its dimin-
ution; however, other post-translational mechanisms are
waiting to be investigated. In conclusion, we have demon-
strated a novel molecular mechanism of VFL to explain its
anti-invasive effect.
In the last few years, differentiation therapy came
out as a novel strategy for treating cancers. This ap-
proach is based on the concept that cancer cells arise
from tissue stem cells and share the stemness and plas-
ticity with normal stem cells. Differentiation therapy
aims to induce cancer cells to differentiate by treat-
ment with differentiation-inducing agents [46,47]. Most
of the differentiation agents can inhibit proliferation andinduce cells to differentiate and then undergo apoptosis
[48,49]. It is well established that VFL blocks mitosis at
the metaphase/anaphase transition, leading to apoptosis
[50]. It is still necessary to elucidate how VFL could
modulate epithelial cell differentiation and cell death;
however, it appears to be an important therapeutic strat-
egy for transitional cell carcinomas by its influence on
these processes. Understanding the differentiation mecha-
nisms and the fate of the treated cells may eventually lead
us to gain insights into cancer therapy by differentiation.
Cadherins are key mediators of cell-to-cell adhesion in
epithelial tissues. The roles of these proteins in bladder
cancer-related EMT have been investigated extensively.
Bryan and Tselepis summarized the patterns of P-cadherin
and N-cadherin expression in the bladder during EMT
[51]. In the normal urothelium, P-cadherin, but not
N-cadherin, is expressed in the basal layer. However,
during the EMT, P-cadherin expression in bladder
cancer cells is upregulated along with N-cadherin ex-
pression; these events occur either independently or
synchronously. E-cadherin expression in bladder can-
cer cells is lost after changes in P- and/or N-cadherin
expression levels, as invasion and metastasis increase.
This cadherin switching event is an important process
that occurs late in the molecular pathogenesis of
bladder cancer; although the precise timing and na-
ture of these events remain unknown. On the other
hand, the mesenchymal intermediate filament, vimen-
tin, often increases its expression in carcinoma cells
that have undergone an EMT. However, under VFL
treatment, vimentin downregulation is observed in
UMUC3 cell line but not in 5637. Vimentin levels are not
always affected during the reversion of mesenchymal-to-
epithelial transition. Indeed, partial EMT has been sug-
gested to occur in some metastatic cancers, where distant
metastasis can retain much of the epithelial differentiation
of the original tissue of the cancer [52]. For instance,
under silibinin treatment, a natural agent that reverses
EMT, vimentin mesenchymal marker was not always in-
fluenced by this agent. Indeed, it was observed that vimen-
tin was not always regulated by silibinin during MET and
this modulation was dependent on the type of prostate
epithelial tumor cells [53,54]. Various lines of evidence
clearly indicate that the EMT is strongly associated with
aggressive bladder cancer behavior, such as recurrence,
progression, and metastasis, an observation that raises the
possibility that the EMT may be a target for bladder
cancer treatment. As mentioned above, E-cadherin is
the first and most important regulator of the EMT.
Moreover, in bladder cancer, loss of E-cadherin ex-
pression is a marker of poor response to the monoclo-
nal antibody cetuximab, which blocks EGFR binding
and represses bladder cancer cell proliferation [55].
Thus, E-cadherin expression levels could constitute an
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microtubule-targeting VFL therapy.
Several studies have demonstrated the influence of the
microtubules on cadherin-dependent cell-cell adhesions.
Kitase et. al. demonstrated that RhoA is implicated dur-
ing neurodetermination, where it influences cell-cell
contact and cadherin levels [56]. They used the P19 cell
model of neuronal differentiation to show that RhoA af-
fects cadherin protein level and cell-cell contacts during
neuroinduction. RhoGTPases have an important role
during neurite growth, axonal guidance, and synaptogen-
esis [57-59]. The cellular effects of RhoA are mediated
by ROCK and seem to involve microtubules, pointing,
for the first time, at the existence of a potential complex
cross-talk between RhoA/ROCK, N-cadherin, and micro-
tubules. The effect on cadherin level occurred in the tim-
ing that corresponds to the switch of E- to N-cadherin
that trigger neurodifferentiation [60]. N-cadherin level ap-
pears to be critical for cell fate determination during mor-
phogenesis. Advanced induction of Cdc42 had similar
effects to RhoA inactivation, underscoring the importance
of correct timing of RhoGTPases during neurodifferentia-
tion [56].
Similar to VFL, another microtubule destabilizing
agent, nocodazole, influenced cell-cell adhesions. The
study reporting these findings examined the role of mi-
crotubules on the transcriptional regulation of cell adhe-
sion proteins, providing evidence that the microtubule
cytoskeleton critically affects EMT by regulating TGF-β/
SMAD2 signaling during palatal fusion and prevents
E-cadherin repression [61]. During palatal fusion, the
midline epithelial seam (MES) degrades to achieve
mesenchymal confluence. EMT is one of the mechanisms
that function during MES degradation. TGF-β induces
EMT in medial edge epithelium (MEE) by down-regulating
the epithelial marker E-cadherin. Microtubule disassembly
impaired palatal fusion leading to a multi-layered MES in
the mid-region and inhibited palatal fusion accompanied
by the development of a multi-layered MES in the mid-
palatal region [62]. The authors further showed that treat-
ment with nocodazole led to the accumulation of cell-cell
adhesion proteins at intercellular junctions in medial edge
epithelium [61]. Microtubule disruption by nocodazole
triggered the aberrant accumulation of E-cadherin adhe-
sion at intercellular junctions in MEE. Due to the aberrant
expression of both negative (Snail and Zeb) and positive
(c-MYC) E-cadherin transcriptional regulators when the
TGF-β/SMAD2 signaling pathway was blocked, resulted in
failure for EMT to progress. These data also support the
important role of the microtubule cytoskeleton in mediat-
ing TGF-β/SMAD2 signals to control E-cadherin expres-
sion in MEE during palatal fusion [61].
Several lines of evidence support that the interaction
of the microtubules with cadherin affects cadherinbiology [63]. First, the junctional integrity of cadherin
is perturbed by drugs such as nocodazole and VFL,
which disrupt microtubules. Second, specific targeting
of microtubule-binding proteins found at junctions
also impairs broad aspects of cadherin biology. For ex-
ample, Nezha-bound microtubules at their minus ends
and tethered them to the zonula adherens. In cultured
mammalian epithelial cells, depletion of either Nezha or
PLEKHA7, which is responsible for recruiting Nezha to
p120-ctn, disrupted the ability of cells to concentrate
E-cadherin to the apical junction of the zonula adherens.
The functional impact of these junctional microtubule-
binding proteins further supports the idea that microtu-
bules that interact with cadherin adhesions are responsible
for regulating junctional integrity. Still, how microtubules
influence these diverse aspects of cadherin biology is com-
plex and poorly understood. Microtubules are commonly
implicated in directing intracellular traffic of membrane-
bound vesicles or molecular complexes; accordingly, it
was postulated to influence cadherins through their intra-
cellular traffic. Indeed, a number of microtubule-based
motors have been identified that support intracellular
transport of cadherins [64].
The EMT is regarded as a key process that allows can-
cer cells to migrate to adjacent organs or metastasize to
distant sites. In bladder cancer, EMT is closely associ-
ated with grave clinical characteristics, such as recur-
rence, progression, metastasis, and reduced survival.
However, metastases of the most common human cancers
(well- to moderately-differentiated carcinomas) often show
a re-differentiation in the sense of a mesenchymal-
epithelial transition (MET). Therefore, strategies to in-
duce reversal EMT (MET), such as VFL, might be able
to suppress cancer cell migration and metastasis. How-
ever, this issue is controversial, as several lines of evi-
dence support that transient dedifferentiation (EMT)
and re-differentiation (MET) processes are a driving
force in metastasis [65]. Although many clinical reports
fostered the concept of transient EMT-MET switches in
metastasis, only little experimental evidence is available
[66]. Chaffer et al. support the role of an EMT in dissem-
ination and the need of a MET for efficient metastasis in
bladder cancer metastasis [66]. Two reports support the
need of re-differentiation (MET) for the colonization and
metastasis of differentiated carcinomas and implicate
EMT-associated growth arrest in these events [67-69].
Therefore, MET has a key clinical impact for future thera-
peutic strategies against metastasis. On one hand, EMT-
targeting therapy may be useful as a personalized
medicine approach that complements conventional
bladder cancer treatments, while on the other hand, the
induction of differentiation and targeting EMT alone
might be counterproductive by activating the proliferation
of disseminated cells. It is possible that therapeutic
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patients diagnosed at early stages of the disease to pre-
vent invasion and dissemination, while anti-MET drugs
could be potentially benefit patients with established
metastasis. Still, a better understanding of the molecu-
lar mechanisms of the EMT in bladder cancer is cru-
cial to the development of new therapeutic modalities
for this cancer [69,70].
Conclusions
Our data suggest that VFL, a microtubule-targeting
drug, may be involved in a cross-talk between micro-
tubule networks and cell-cell adhesions. We suggest a
novel molecular mechanism by which VFL may impact
upon EMT and metastasis. VFL impacts on E-cadherin-
based cell-cell adhesion and influence on the EMT
markers in epithelial bladder tumour cell lines. We have
shown that VFL induces cell death in bladder cancer cells
and activates epithelial differentiation of the remaining living
cells. VFL increases E-cadherin dependent cell-cell adhesion,
and reduces vimentin and N-cadherin mesenchymal
markers. Moreover, the levels of the E3 ubiquitin-
ligase Hakai were reduced by VFL in 5637 suggesting
that proteasome-dependent mechanism could be one
of the molecular mechanisms implicated in this reduc-
tion. Our findings suggest the existence of a new
mechanism of VFL-microtubule targeting drug to cell-
cell contacts with potential functional implications in
the maintenance of epithelial cell phenotype.
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